Navigating EGFR Mutations and ALK Fusions in Early-Stage Non-Small Cell Lung Cancer
Pharmacy Times
JUNE 19, 2025
1 Biomarker testing is relatively new in the treatment landscape for NSCLC but has proven incredibly important for personalizing patient care, transforming from a generic chemotherapy approach to a highly personalized, genomically driven treatment strategy. For advanced disease, chemotherapy was the standard.
Let's personalize your content